Атеротромбоз (May 2017)
SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME
Abstract
The current clinical guidelines for the treatment of patients with acute coronary syndrome (ACS) claim that simultaneous use of two drugs that inhibit platelet activity is mandatory for most patients. This approach known as dual antiplatelet therapy (DAT), in view of the similarity of the mechanisms of the disease development, should be used in both ACS with ST elevation (STE-ACS) and in ACS without ST elevation (non-STE-ACS). In both cases, DAT should combine acetylsalicylic acid (ASA) with a P2Y12 receptor antagonist (ticagrelor, prasugrel or clopidogrel). For Russia, where prasugrel is not registered, the most preferable DAT is the combination of ASA with ticagrelor which has outperformed clopidogrel in terms of efficacy in the PLATO trial. [1]
Keywords